Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Top Cited Papers
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (7), 844-860
- https://doi.org/10.1016/j.annonc.2020.03.304
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma
- Janssen Biotech
- Bayer
- Novartis Pharma
- Ipsen Biopharmaceuticals
This publication has 101 references indexed in Scilit:
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR InhibitorsClinical Cancer Research, 2012
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine TumorsClinical Cancer Research, 2010
- Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumoursAlimentary Pharmacology & Therapeutics, 2009
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone ScintigraphyJournal of Nuclear Medicine, 2009
- Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic diseaseBritish Journal of Surgery, 2009
- Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasmsCancer, 2008
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2001
- Interferon in the Management of Neuroendocrine GEP-TumorsDigestion, 2000
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaThe New England Journal of Medicine, 1992